Abeona Therapeutics Inc.

4.20-0.0600-1.41%Vol 490.60K1Y Perf -86.69%
Aug 5th, 2022 16:00 DELAYED
BID4.15 ASK4.42
Open4.20 Previous Close4.26
Pre-Market- After-Market4.17
 - -  -0.03 -0.71%
Target Price
20.00 
Analyst Rating
Moderate Buy 2.00
Potential %
376.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     45.38
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
3.07 
Earnings Rating
Strong Buy
Market Cap24.67M 
Earnings Date
10th Aug 2022
Alpha-0.03 Standard Deviation0.25
Beta1.24 

Today's Price Range

4.104.42

52W Range

3.2634.00

5 Year PE Ratio Range

-9.50-2.90

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
6.06%
1 Month
10.53%
3 Months
2.19%
6 Months
-34.04%
1 Year
-86.69%
3 Years
-93.06%
5 Years
-97.91%
10 Years
-

TickerPriceChg.Chg.%
ABEO4.20-0.0600-1.41
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
ProfitabilityValueIndustryS&P 500US Markets
-
-2 608.30
-2 474.10
-2 180.30
-
RevenueValueIndustryS&P 500US Markets
3.35M
0.57
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-2.00-2.50-25.00
Q04 2021-3.25-3.50-7.69
Q03 2021-4.00-4.000.00
Q02 2021-4.00-4.000.00
Q01 2021-4.75-4.2510.53
Q04 2020-0.09-0.17-88.89
Q03 2020-0.13-0.0838.46
Q02 2020-0.17-0.1417.65
Earnings Per EndEstimateRevision %Trend
6/2022 QR-1.2528.57Positive
9/2022 QR-1.0020.00Positive
12/2022 FY-3.5057.58Positive
12/2023 FY-2.5432.27Positive
Next Report Date10th Aug 2022
Estimated EPS Next Report-1.25
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume490.60K
Shares Outstanding5.87K
Shares Float5.80M
Trades Count1.94K
Dollar Volume2.09M
Avg. Volume566.53K
Avg. Weekly Volume302.13K
Avg. Monthly Volume216.16K
Avg. Quarterly Volume1.18M

Abeona Therapeutics Inc. (NASDAQ: ABEO) stock closed at 4.2 per share at the end of the most recent trading day (a -1.41% change compared to the prior day closing price) with a volume of 490.60K shares and market capitalization of 24.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Abeona Therapeutics Inc. CEO is Vishwas Seshadri.

The one-year performance of Abeona Therapeutics Inc. stock is -86.69%, while year-to-date (YTD) performance is -50.15%. ABEO stock has a five-year performance of -97.91%. Its 52-week range is between 3.2575 and 34, which gives ABEO stock a 52-week price range ratio of 3.07%

Abeona Therapeutics Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.91, a price-to-sale (PS) ratio of 8.25, a price to cashflow ratio of 30.00, a PEG ratio of 2.32, a ROA of -95.09%, a ROC of -121.80% and a ROE of -148.83%. The company’s profit margin is -%, its EBITDA margin is -2 474.10%, and its revenue ttm is $3.35 Million , which makes it $0.57 revenue per share.

Of the last four earnings reports from Abeona Therapeutics Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.25 for the next earnings report. Abeona Therapeutics Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Abeona Therapeutics Inc. is Moderate Buy (2), with a target price of $20, which is +376.19% compared to the current price. The earnings rating for Abeona Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Abeona Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Abeona Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.04, ATR14 : 0.39, CCI20 : -50.34, Chaikin Money Flow : -0.52, MACD : 0.47, Money Flow Index : 66.66, ROC : -17.32, RSI : 30.01, STOCH (14,3) : 29.10, STOCH RSI : 0.73, UO : 34.44, Williams %R : -70.90), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Abeona Therapeutics Inc. in the last 12-months were: Brendan M. O'Malley (Sold 43 494 shares of value $36 201 ), Mark J. Alvino (Sold 55 000 shares of value $8 562 ), Michael Amoroso (Sold 45 409 shares of value $49 382 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.

CEO: Vishwas Seshadri

Telephone: +1 646 813-4701

Address: 1330 Avenue of the Americas, New York 10019, NY, US

Number of employees: 90

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

59%41%

Bearish Bullish

69%31%

Bearish Bullish

62%38%


News

Stocktwits